Research Interests
My primary research interest involves investigating novel cellular therapy and stem cell transplant strategies, along with ways to ameliorate their toxicities. I have a secondary interest in the application of teleoncology to overcome barriers to cancer care for underserved populations.
Selected Grants
Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease
Clinical TrialPrincipal Investigator · Awarded by Rigel Pharmaceuticals, Inc. · 2024 - 2029Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2024 - 2029Digital Multi-Vital Sign Monitoring for Early Detection of Cytokine Release Syndrome from Bispecific T-Cell Engagers and Chimeric Antigen Receptor Therapy
Clinical TrialPrincipal Investigator · Awarded by Blue Spark Technologies, Inc. · 2024 - 2029A Phase 1b/2a Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients with Diffuse Large B-cell Lymphoma Receiving CAR T-cell Therapy
Clinical TrialPrincipal Investigator · Awarded by CytoAgents, Inc. · 2024 - 2029Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchInvestigator · Awarded by National Institutes of Health · 2015 - 2026Fellowships, Gifts, and Supported Research
THRIVE Pre-CDA Award ·
2023
- 2023
Awarded by: Department of Veterans Affairs
Pilot Award ·
2023
- 2025
Awarded by: Leukemia & Lymphoma Society
Duke Hematology & Transfusion Medicine T32 ·
2021
- 2023
Awarded by: NIH/NHLBI
External Relationships
- Autolus
- Rigel Pharmaceuticals, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.